{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T23:23:44Z","timestamp":1774653824731,"version":"3.50.1"},"reference-count":18,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2021,2,15]],"date-time":"2021-02-15T00:00:00Z","timestamp":1613347200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Virchow Biotech"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,5,20]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Currently, there is no specific drug for the treatment of coronavirus disease 2019 (COVID-19). Therapeutic benefits of intravenous immunoglobulin (IVIG) have been demonstrated in wide range of diseases. The present study is conducted to evaluate the safety and efficacy of IVIG in the treatment of COVID-19 patients with moderate pneumonia.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>An open-label, multicenter, comparative, randomized study was conducted on COVID-19 patients with moderate pneumonia. One hundred eligible patients were randomized in 1:1 ratio either to receive IVIG + standard of care (SOC) or SOC.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Duration of hospital stay was significantly shorter in the IVIG group compared with that of SOC alone (7.7 vs 17.5 days). Duration for normalization of body temperature, oxygen saturation, and mechanical ventilation were significantly shorter in IVIG compared with SOC. Percentages of patients on mechanical ventilation in 2 groups were not significantly different (24% vs 38%). Median time to reverse-transcription polymerase chain reaction negativity was significantly shorter with IVIG than SOC (7 vs 18 days). There were only mild to moderate adverse events in both groups except for 1 patient (2%), who died in SOC.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Intravenous immunoglobulin was safe and efficacious as an adjuvant with other antiviral drugs in the treatment of COVID-19.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/infdis\/jiab098","type":"journal-article","created":{"date-parts":[[2021,2,12]],"date-time":"2021-02-12T12:19:11Z","timestamp":1613132351000},"page":"1538-1543","source":"Crossref","is-referenced-by-count":33,"title":["A Phase II Safety and Efficacy Study on Prognosis of Moderate Pneumonia in Coronavirus Disease 2019 Patients With Regular Intravenous Immunoglobulin Therapy"],"prefix":"10.1093","volume":"223","author":[{"given":"R S","family":"Raman","sequence":"first","affiliation":[{"name":"Department of Medicine, Maharaja Agrasen Hospital, New Delhi, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vijaykumar","family":"Bhagwan Barge","sequence":"additional","affiliation":[{"name":"Department of Medicine, Rajshree Chhatrapati Shahu Maharaj Government Medical College and CPR Hospital, Kolhapur, Maharashtra, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Darivenula","family":"Anil Kumar","sequence":"additional","affiliation":[{"name":"Department of General Medicine, Gandhi Medical College and Hospital, Hyderabad, Telangana, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Himanshu","family":"Dandu","sequence":"additional","affiliation":[{"name":"Department of Medicine, King George\u2019s Medical College, Lucknow, Uttar Pradesh, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R","family":"Rakesh Kartha","sequence":"additional","affiliation":[{"name":"Department of Medicine, Maharaja Agrasen Hospital, New Delhi, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Varun","family":"Bafna","sequence":"additional","affiliation":[{"name":"Department of Medicine, Rajshree Chhatrapati Shahu Maharaj Government Medical College and CPR Hospital, Kolhapur, Maharashtra, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vishaly T","family":"Aravinda","sequence":"additional","affiliation":[{"name":"Department of Medical Affairs, Virchow Biotech Pvt. Ltd., Hyderabad, Telangana, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thummala C","family":"Raghuram","sequence":"additional","affiliation":[{"name":"Department of Medical Affairs, Virchow Biotech Pvt. Ltd., Hyderabad, Telangana, India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2021,2,15]]},"reference":[{"key":"2021052019530695600_CIT0001","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"10223","author":"Huang","year":"2020","journal-title":"Lancet"},{"key":"2021052019530695600_CIT0002","author":"WHO Solidarity Trial Consortium"},{"key":"2021052019530695600_CIT0003","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/S0140-6736(20)31022-9","article-title":"Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial","volume":"395","author":"Wang","year":"2020","journal-title":"Lancet"},{"key":"2021052019530695600_CIT0004","doi-asserted-by":"crossref","first-page":"s1","DOI":"10.1016\/j.jaci.2016.09.023","article-title":"Update on the use of immunoglobulin in human disease: a review of evidence","volume":"139","author":"Perez","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"2021052019530695600_CIT0005","doi-asserted-by":"crossref","first-page":"818","DOI":"10.3201\/eid1005.030640","article-title":"Clinical manifestations, laboratory findings, and treatment outcomes of SARS patients","volume":"10","author":"Wang","year":"2004","journal-title":"Emerg Infect Dis"},{"key":"2021052019530695600_CIT0006","doi-asserted-by":"crossref","first-page":"389","DOI":"10.7326\/M13-2486","article-title":"Clinical course and outcomes of critically ill patients with Middle East respiratory syndrome coronavirus infection","volume":"160","author":"Arabi","year":"2014","journal-title":"Ann Intern Med"},{"key":"2021052019530695600_CIT0007","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1378\/chest.12-2907","article-title":"Hyperimmune IV immunoglobulin treatment: a multicentre double-blind randomized controlled trial for patients with severe 2009 influenza A (H1N1) infection","volume":"144","author":"Hung","year":"2013","journal-title":"Chest"},{"key":"2021052019530695600_CIT0008","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1159\/000512727","article-title":"Intravenous immunoglobulin for the treatment of COVID-19: a promising tool","volume":"99","author":"Tzilas","year":"2020","journal-title":"Respiration"},{"key":"2021052019530695600_CIT0009","doi-asserted-by":"crossref","DOI":"10.1002\/cti2.1192","article-title":"Clinical efficacy of intravenous immunoglobulin therapy in critical ill patients with COVID-19: a multicenter retrospective cohort study","author":"Shao","year":"2020","journal-title":"Clin Transl Immunology"},{"key":"2021052019530695600_CIT0010","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1186\/s12879-020-05507-4","article-title":"The use of intravenous immunoglobulin gamma for the treatment of severe coronavirus disease 2019: a randomized placebo-controlled double-blind clinical trial","volume":"20","author":"Gharebaghi","year":"2020","journal-title":"BMC Infect Dis"},{"key":"2021052019530695600_CIT0011","article-title":"Intravenous immunoglobulin","author":"Sakoulas"},{"key":"2021052019530695600_CIT0012","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1159\/000511376","article-title":"Use of intravenous immunoglobulin for the treatment of COVID-19: retrospective case series","volume":"99","author":"Herth","year":"2020","journal-title":"Respiration"},{"key":"2021052019530695600_CIT0013","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1001\/jama.2020.2648","article-title":"Characteristics of and importance lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese center for disease control and prevention","volume":"323","author":"Wu","year":"2020","journal-title":"JAMA"},{"key":"2021052019530695600_CIT0014","article-title":"Outcome of hospitalized patients with COVID-19 pneumonia treated with high-dose immunoglobulin therapy in a prospective case series","author":"Reynaga","year":"2020","journal-title":"CMI"},{"key":"2021052019530695600_CIT0015","doi-asserted-by":"crossref","first-page":"2000547","DOI":"10.1183\/13993003.00547-2020","article-title":"Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis","volume":"55","author":"Guan","year":"2020","journal-title":"Eur Respir J"},{"key":"2021052019530695600_CIT0016","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.jinf.2020.03.044","article-title":"Effect of regular intravenous immunoglobulin therapy on prognosis of severe pneumonia in patients with COVID-19","volume":"81","author":"Xie","year":"2020","journal-title":"J Infect"},{"key":"2021052019530695600_CIT0017","author":"Hanafi"},{"key":"2021052019530695600_CIT0018","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1136\/adc.2005.078733","article-title":"A prospective study of the immediate and delayed adverse events following intravenous immunoglobulin infusions","volume":"91","author":"Singh-Grewal","year":"2006","journal-title":"Arch Dis Child"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiab098\/37062216\/jiab098.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jid\/article-pdf\/223\/9\/1538\/38017939\/jiab098.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jid\/article-pdf\/223\/9\/1538\/38017939\/jiab098.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,20]],"date-time":"2021-05-20T19:53:24Z","timestamp":1621540404000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/223\/9\/1538\/6135116"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,15]]},"references-count":18,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2021,2,15]]},"published-print":{"date-parts":[[2021,5,20]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiab098","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,5,1]]},"published":{"date-parts":[[2021,2,15]]}}}